Effect of valproic acid on the outcome of glioblastoma multiforme

References

• Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977–2000. Cancer 2004;101:x2293–9.
   PubMed Web of Science ®Google Scholar
• Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994;34: 45–60; discussion 60–41.
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR, . A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190–8.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Mazzarella G, Osti MF, . Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. Anticancer Drugs 2006;17:969–75.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Buyukberber S. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori 2009;95:191–7.
   PubMed Web of Science ®Google Scholar
• Ashby LS, Ryken TC. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg Focus 2006;20:E3.
   PubMedGoogle Scholar
• Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2010; 17:417–21.
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001;13: 477–83.
   PubMed Web of Science ®Google Scholar
• Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210–16.
   PubMed Web of Science ®Google Scholar
• Chen X, Wong P, Radany E, Wong JY. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 2009;24:689–99.
   PubMed Web of Science ®Google Scholar
• Sarkar D. HDAC inhibitors and ionizing radiation: combinatorial strategy to combat lung cancer. Cancer Biol Ther 2009;8:832–4.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 2010;5:196–208.
   PubMedGoogle Scholar
• Noro R, Miyanaga A, Minegishi Y, . Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21 expression. Cancer Sci 2010;101:1424–30.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, . Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31–9.
   PubMed Web of Science ®Google Scholar
• Kavanaugh SA, White LA, Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 2010;67:793–7.
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ, . Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009;27:2052–8.
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734–41.
   PubMed Web of Science ®Google Scholar
• Blaheta RA, Michaelis M, Driever PH, Cinatl J, Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005;25:383–97.
   PubMed Web of Science ®Google Scholar
• Candelaria M, Gallardo-Rincon D, Arce C, . A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007;18:1529–38.
   PubMed Web of Science ®Google Scholar
• Noguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y, Maruta J, . Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 2009;56:245–9.
   PubMed Web of Science ®Google Scholar
• Rocca A, Minucci S, Tosti G, . A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009;100:28–36.
   PubMed Web of Science ®Google Scholar
• Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 2009;33:779–87.
   PubMed Web of Science ®Google Scholar
• Sharma S, Symanowski J, Wong B, Dino P, Manno P, Vogelzang N. A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy. Transl Oncol 2008;1:141–7.
   PubMed Web of Science ®Google Scholar
• Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5.
   PubMed Web of Science ®Google Scholar
• Driever PH, Knupfer MM, Cinatl J, Wolff JE. Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr 1999;211:323–8.
   PubMed Web of Science ®Google Scholar
• Driever PH, Wagner S, Hofstadter F, Wolff JE. Valproic acid induces differentiation of a supratentorial primitive neuroectodermal tumor. Pediatr Hematol Oncol 2004;21:743–51.
   PubMed Web of Science ®Google Scholar
• Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005;72:255–60.
   PubMed Web of Science ®Google Scholar
• Witt O, Schweigerer L, Driever PH, Wolff J, Pekrun A. Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 2004;43:181.
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M, . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745–51.
   PubMed Web of Science ®Google Scholar
• Miller PJ, Hassanein RS, Giri PG, Kimler BF, O’Boynick P, Evans RG. Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors. Int J Radiat Oncol Biol Phys 1990;19:275–80.
   PubMed Web of Science ®Google Scholar
• Ozbek N, Cakir S, Gursel B, Meydan D. Prognostic significance of seizure in patients with glioblastoma multiforme. Neurol India 2004;52:76–8.
   PubMed Web of Science ®Google Scholar
• Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. Journal of Neurosurgery 1989;71:487–93.
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Ballman K, Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2009;73:1207–13.
   PubMed Web of Science ®Google Scholar
• Frediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci 2004;25:S161–6.
   PubMed Web of Science ®Google Scholar
• Limdi NA, Knowlton RK, Cofield SS, . Safety of rapid intravenous loading of valproate. Epilepsia 2007;48:478–83.
   PubMed Web of Science ®Google Scholar
• Wolff JE, Kramm C, Kortmann RD, . Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 2008;90:309–314.
   PubMed Web of Science ®Google Scholar
• Masoudi A, Elopre M, Amini E, . Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 2008;28:2437–42.
   PubMed Web of Science ®Google Scholar
• Benitez JA, Arregui L, Cabrera G, Segovia J. Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression. Neuroscience 2008;156:911–20.
   PubMed Web of Science ®Google Scholar
• Das CM, Aguilera D, Vasquez H, . Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007;85:159–70.
   PubMed Web of Science ®Google Scholar
• Knupfer MM, Hernaiz-Driever P, Poppenborg H, Wolff JE, Cinatl J. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res 1998;18:3585–9.
   PubMed Web of Science ®Google Scholar
• Camphausen K, Cerna D, Scott T, . Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005;114:380–6.
   PubMed Web of Science ®Google Scholar
• Ciusani E, Balzarotti M, Calatozzolo C, . Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. Oncol Res 2007;16:453–63.
   PubMed Web of Science ®Google Scholar